- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/24 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 207/24
Total number of patents in this class: 95
10-year publication summary
|
5
|
3
|
7
|
13
|
5
|
3
|
8
|
7
|
6
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10963 |
4 |
| Bristol-myers Squibb Company | 4896 |
3 |
| Merck Patent GmbH | 5831 |
3 |
| BioCryst Pharmaceuticals, Inc. | 175 |
3 |
| Omeros Corporation | 305 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2832 |
3 |
| Vettore, LLC | 13 |
3 |
| 3m Innovative Properties Company | 17848 |
2 |
| Janssen Pharmaceutica N.V. | 3431 |
2 |
| Pfizer Inc. | 3352 |
2 |
| Allergan, Inc. | 2362 |
2 |
| Northwestern University | 3353 |
2 |
| Eli Lilly and Company | 3797 |
2 |
| MedImmune Limited | 607 |
2 |
| National Institute of Biological Sciences, Beijing | 97 |
2 |
| NDSU Research Foundation | 245 |
2 |
| Shanghai Puyi Chemical Technology Co. Ltd | 2 |
2 |
| Vironova Thionation AB | 6 |
2 |
| Evonik Operations GmbH | 4032 |
2 |
| Petra Pharma Corporation | 31 |
2 |
| Other owners | 47 |